The LSL60101 compound, a specific ligand of the I2-IR receptors in the brain, could shed light on the development of future strategies against Alzheimer’s disease. This is stated in the recent studies by the Research Group on Medicinal Chemistry and Pharmacology of Neurodegenerative Diseases of the University of Barcelona, published in the journals European Journal of Medicinal Chemistry and British Journal Pharmacology. In studies carried out with mice, LSL60101 has improved the cognitive deficit and the biomarkers related to the disease in these animal models.

These studies result from the collaboration of the research teams led by professors Carmen Escolano, from the Faculty of Pharmacy and Food Sciences and the Institute of Biomedicine of the UB (IBUB), and Mercè Pallàs, from the same Faculty and the Institute of Neurosciences (UBNeuro). Framed within a program in the CaixaImpulse program, the studies are also signed by the UB researchers Christian Griñán Ferré, Foteinin Vasilopoulou, Sergio Rodríguez Arévalo and Andrea Bagán. Among the participants are teams of the Autonomous University of Barcelona, the University of the Balearic Islands, the University of Santiago de Compostela, the University of the Basque Country, CIBERSAM, Rega Institute for Medical Research (Belgium), the University of Belgrade (Servia), and others.

More